Whan In Pharm Co.,Ltd. (016580.KS)
KRW 11930.0
(-0.33%)
KRW 11930.0
(-0.33%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 54.05 Billion KRW | 45.87% |
| 2022 | 37.05 Billion KRW | 13.18% |
| 2021 | 32.74 Billion KRW | -0.06% |
| 2020 | 32.76 Billion KRW | 16.11% |
| 2019 | 28.21 Billion KRW | 8.96% |
| 2018 | 25.89 Billion KRW | 21.33% |
| 2017 | 21.34 Billion KRW | 15.23% |
| 2016 | 18.52 Billion KRW | -9.63% |
| 2015 | 20.49 Billion KRW | 7.62% |
| 2014 | 19.04 Billion KRW | 19.19% |
| 2013 | 15.97 Billion KRW | 10.68% |
| 2012 | 14.43 Billion KRW | 17.28% |
| 2011 | 12.31 Billion KRW | -14.26% |
| 2010 | 14.35 Billion KRW | 17.97% |
| 2009 | 12.17 Billion KRW | -0.57% |
| 2008 | 12.24 Billion KRW | 59.72% |
| 2007 | 7.66 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 67.73 Billion KRW | 11.51% |
| 2024 Q1 | 60.74 Billion KRW | 12.37% |
| 2023 FY | 54.05 Billion KRW | 45.87% |
| 2023 Q4 | 54.05 Billion KRW | 6.12% |
| 2023 Q3 | 50.93 Billion KRW | 3.52% |
| 2023 Q2 | 49.2 Billion KRW | 14.46% |
| 2023 Q1 | 42.98 Billion KRW | 16.0% |
| 2022 Q3 | 35.76 Billion KRW | 3.24% |
| 2022 Q2 | 34.63 Billion KRW | -0.49% |
| 2022 FY | 37.05 Billion KRW | 13.18% |
| 2022 Q4 | 37.05 Billion KRW | 3.63% |
| 2022 Q1 | 34.8 Billion KRW | 6.3% |
| 2021 Q3 | 31.09 Billion KRW | -4.09% |
| 2021 FY | 32.74 Billion KRW | -0.06% |
| 2021 Q1 | 30.31 Billion KRW | -7.46% |
| 2021 Q2 | 32.42 Billion KRW | 6.94% |
| 2021 Q4 | 32.74 Billion KRW | 5.3% |
| 2020 FY | 32.76 Billion KRW | 16.11% |
| 2020 Q1 | 26.73 Billion KRW | -5.26% |
| 2020 Q2 | 27.82 Billion KRW | 4.07% |
| 2020 Q3 | 26.72 Billion KRW | -3.93% |
| 2020 Q4 | 32.76 Billion KRW | 22.58% |
| 2019 Q1 | 26.05 Billion KRW | 0.62% |
| 2019 FY | 28.21 Billion KRW | 8.96% |
| 2019 Q4 | 28.21 Billion KRW | 3.1% |
| 2019 Q3 | 27.37 Billion KRW | -1.6% |
| 2019 Q2 | 27.81 Billion KRW | 6.75% |
| 2018 Q2 | 19.52 Billion KRW | -6.24% |
| 2018 FY | 25.89 Billion KRW | 21.33% |
| 2018 Q4 | 25.89 Billion KRW | 32.6% |
| 2018 Q3 | 19.53 Billion KRW | 0.02% |
| 2018 Q1 | 20.82 Billion KRW | -2.43% |
| 2017 FY | 21.34 Billion KRW | 15.23% |
| 2017 Q3 | 19.47 Billion KRW | -5.37% |
| 2017 Q4 | 21.34 Billion KRW | 9.6% |
| 2017 Q1 | 19.63 Billion KRW | 5.99% |
| 2017 Q2 | 20.58 Billion KRW | 4.83% |
| 2016 Q1 | 20.55 Billion KRW | 0.27% |
| 2016 Q3 | 19.08 Billion KRW | -7.17% |
| 2016 Q4 | 18.52 Billion KRW | -2.93% |
| 2016 FY | 18.52 Billion KRW | -9.63% |
| 2016 Q2 | 20.55 Billion KRW | 0.0% |
| 2015 Q4 | 20.49 Billion KRW | 0.37% |
| 2015 Q1 | 20.58 Billion KRW | 8.09% |
| 2015 Q3 | 20.42 Billion KRW | 0.28% |
| 2015 Q2 | 20.36 Billion KRW | -1.07% |
| 2015 FY | 20.49 Billion KRW | 7.62% |
| 2014 Q4 | 19.04 Billion KRW | 15.7% |
| 2014 FY | 19.04 Billion KRW | 19.19% |
| 2014 Q3 | 16.46 Billion KRW | -2.86% |
| 2014 Q2 | 16.94 Billion KRW | 0.76% |
| 2014 Q1 | 16.81 Billion KRW | 5.25% |
| 2013 Q4 | 15.97 Billion KRW | 1.31% |
| 2013 FY | 15.97 Billion KRW | 10.68% |
| 2013 Q1 | 13.64 Billion KRW | -5.51% |
| 2013 Q2 | 14.45 Billion KRW | 5.98% |
| 2013 Q3 | 15.77 Billion KRW | 9.09% |
| 2012 Q1 | 11.65 Billion KRW | -5.33% |
| 2012 Q4 | 14.43 Billion KRW | 18.72% |
| 2012 Q2 | 15.36 Billion KRW | 31.86% |
| 2012 FY | 14.43 Billion KRW | 17.28% |
| 2012 Q3 | 12.16 Billion KRW | -20.87% |
| 2011 Q2 | 19.28 Billion KRW | 31.56% |
| 2011 Q1 | 14.66 Billion KRW | 2.11% |
| 2011 Q3 | 14.4 Billion KRW | -25.3% |
| 2011 FY | 12.31 Billion KRW | -14.26% |
| 2011 Q4 | 12.31 Billion KRW | -14.55% |
| 2010 Q3 | 12.9 Billion KRW | 17.31% |
| 2010 Q2 | 11 Billion KRW | -2.16% |
| 2010 Q4 | 14.35 Billion KRW | 11.27% |
| 2010 Q1 | 11.24 Billion KRW | -7.63% |
| 2010 FY | 14.35 Billion KRW | 17.97% |
| 2009 Q3 | 12.18 Billion KRW | 5.7% |
| 2009 FY | 12.17 Billion KRW | -0.57% |
| 2009 Q2 | 11.52 Billion KRW | -3.46% |
| 2009 Q1 | 11.94 Billion KRW | -2.44% |
| 2009 Q4 | 12.17 Billion KRW | -0.13% |
| 2008 Q2 | 9.24 Billion KRW | 26.56% |
| 2008 Q3 | 10.9 Billion KRW | 17.98% |
| 2008 Q4 | 12.24 Billion KRW | 12.22% |
| 2008 FY | 12.24 Billion KRW | 59.72% |
| 2008 Q1 | 7.3 Billion KRW | -4.68% |
| 2007 Q3 | 7.91 Billion KRW | -1.77% |
| 2007 Q4 | 7.66 Billion KRW | -3.16% |
| 2007 FY | 7.66 Billion KRW | 0.0% |
| 2007 Q1 | 6.53 Billion KRW | 0.0% |
| 2007 Q2 | 8.05 Billion KRW | 23.31% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -22.436% |
| Dong-A Socio Holdings Co., Ltd. | 117.85 Billion KRW | 54.131% |
| Ildong Holdings Co., Ltd. | 91.16 Billion KRW | 40.704% |
| HANDOK Inc. | 94.46 Billion KRW | 42.774% |
| Kukje Pharma Co., Ltd. | 21.24 Billion KRW | -154.473% |
| Yuhan Corporation | 284.75 Billion KRW | 81.016% |
| Dong-A ST Co., Ltd. | 116.31 Billion KRW | 53.524% |
| SAMSUNG PHARM. Co., LTD. | 16.25 Billion KRW | -232.487% |
| Hanmi Pharm. Co., Ltd. | 288.81 Billion KRW | 81.283% |
| Hanall Biopharma Co.,Ltd | 32.38 Billion KRW | -66.927% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | 12.421% |
| Dong Sung Bio Pharm.Co.,Ltd. | 19.47 Billion KRW | -177.547% |
| MYUNGMOON Pharm co.,Ltd | 30.28 Billion KRW | -78.525% |
| Hana Pharm Co., Ltd. | 48.34 Billion KRW | -11.812% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -22.436% |
| Ilsung Pharmaceuticals Co., Ltd. | 31.24 Billion KRW | -73.036% |
| REYON Pharmaceutical Co., Ltd. | 35.17 Billion KRW | -53.677% |
| Aprogen pharmaceuticals,Inc. | 48.12 Billion KRW | -12.321% |
| JW Holdings Corporation | 147.58 Billion KRW | 63.373% |
| Ildong Pharmaceutical Co., Ltd. | 84.62 Billion KRW | 36.119% |
| Chong Kun Dang Pharmaceutical Corp. | 261.43 Billion KRW | 79.322% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 49.046% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -0.25% |
| Hyundai Pharmaceutical Co., Ltd. | 26.99 Billion KRW | -100.23% |
| Samil Pharmaceutical Co.,Ltd | 32.51 Billion KRW | -66.274% |
| Jeil Pharmaceutical Co.,Ltd | 109.76 Billion KRW | 50.753% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -22.436% |
| Kwang Dong Pharmaceutical Co., Ltd. | 188.64 Billion KRW | 71.344% |
| Daewoong pharmaceutical Co.,Ltd | 241.54 Billion KRW | 77.62% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 49.046% |
| Yuhan Corporation | 284.75 Billion KRW | 81.016% |
| Jeil Pharma Holdings Inc | 125.28 Billion KRW | 56.85% |
| Yungjin Pharm. Co., Ltd. | 61.98 Billion KRW | 12.791% |
| Suheung Co., Ltd. | 259.84 Billion KRW | 79.196% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 49.046% |
| Samjin Pharmaceuticals Co., Ltd. | 79.6 Billion KRW | 32.09% |
| Korea United Pharm Inc. | 49.14 Billion KRW | -10.003% |
| CKD Bio Corp. | 69.08 Billion KRW | 21.748% |
| Daewon Pharmaceutical Co., Ltd. | 105.07 Billion KRW | 48.554% |
| Dongwha Pharm.Co.,Ltd | 70.69 Billion KRW | 23.536% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -0.25% |
| Chong Kun Dang Holdings Corp. | 194.76 Billion KRW | 72.245% |
| Boryung Corporation | 189.8 Billion KRW | 71.519% |
| Bukwang Pharmaceutical Co., Ltd. | 56.83 Billion KRW | 4.881% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | 12.421% |
| JW Lifescience Corporation | 23.39 Billion KRW | -131.031% |